Eukaryotic Protein Kinases: A Survey of the Pkinase Family (PF00069)

lmmol AI Research Collective · Published 2026-06-24 · lmmol:review:PF00069

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 9,705 papers from lmmol's literature graph. Citations link to their source on PubMed.

1. Overview

Eukaryotic protein kinases constitute one of the largest and most functionally consequential protein families, transducing signals by transferring phosphate onto serine, threonine, and tyrosine residues. The catalogue of the human "kinome" identified 518 putative protein kinase genes, of which 244 map to disease loci or cancer amplicons, establishing the family as both a central node of cellular regulation and a major reservoir of therapeutic targets ^[1]. Members of this family govern metabolism, cell-cycle progression, stress responses, innate immunity, and programmed cell death. The substrate underlying this review spans 3,186 proteins and 9,705 papers, reflecting the breadth of the family, from metazoan signaling enzymes such as Akt/PKB and the cyclin-dependent kinases (CDKs) to plant receptor kinases and yeast stress kinases.

2. Key proteins

Several recurrent enzymes anchor the literature. RAC-alpha serine/threonine-protein kinase (Akt/PKB, P31749) is the most heavily represented protein and a hub of growth-factor signaling. The CDKs — CDK1, CDK2, and CDK9 (P06493, P24941, P50750) — drive cell-cycle and transcriptional control. The MAP kinases ERK2/MAPK1 (P28482), p38/MAPK14 (Q16539), and yeast HOG1 (P32485) define stress- and mitogen-responsive cascades. GSK-3β (P49841) links insulin signaling to metabolic control, while checkpoint kinases Chk1 and Chk2 (O14757, O96017) and Aurora kinase A (O14965) safeguard genome integrity. Disease-associated kinases include LRRK2 (Q5S007) and PINK1 (Q9BXM7) in Parkinson's disease, and the inflammatory/innate-immune kinases TBK1 (Q9UHD2), IKKβ (O14920), and the eIF2α kinase PKR (P19525). The metabolic master switch AMPK is represented through its plant ortholog KIN10 (Q38997), and SGK1 (O00141) and STK11/LKB1 (Q15831) round out the metabolic/tumor-suppressor axis.

3. Structural & mechanistic insights

A unifying theme is activation by phosphorylation within the conserved kinase domain. Akt/PKB activation requires phosphorylation of Thr308 in the activation loop and Ser473 in the C-terminal hydrophobic motif; both are needed for maximal activity and are abolished by PI3-kinase inhibition ^[2]. The activation-loop kinase was purified and named PDK1, a PtdIns(3,4,5)P3-dependent enzyme that phosphorylates Akt Thr308 ^[3], while the elusive Ser473 kinase was later identified as the rictor-mTOR complex ^[4]. The MAP kinases share dual Thr/Tyr phosphorylation for activity: JNK1 is activated by dual phosphorylation during the UV response and phosphorylates c-Jun at Ser63/Ser73 ^[5], a stress-activated subfamily (SAPKs) distinct from ERKs in substrate specificity ^[6], while p38 was cloned as an endotoxin- and osmolarity-responsive kinase sharing phosphorylation-site features with yeast HOG1 ^[7]. The eIF2α kinases PERK and IRE1 are ER-resident transmembrane sensors whose lumenal domains bind the chaperone BiP; misfolding releases BiP and drives oligomerization and activation ^[8][9]. More recent structural work has illuminated activation by partner proteins: cryo-EM revealed how the mitotic kinase NEK7 bridges adjacent NLRP3 subunits to license inflammasome assembly ^[10], and structures of the active NLRP3-NEK7-ASC disc showed an ATP-bound NACHT conformation, with NEK7 acting to break the inactive cage rather than forming the disc interface ^[11].

4. Disease & therapeutic relevance

The kinome's disease links are pervasive. CDK dysregulation drives unscheduled proliferation and chromosomal instability, and although CDK1 is universally required, selective inhibition of interphase CDKs may spare normal cells ^[12]. Akt deregulation underlies cancer and diabetes, with rictor-mTOR proposed as a target in PTEN-null tumors ^[4]. In metabolism, AMPK mediates the action of the antidiabetic drug metformin, reducing hepatic glucose output and lipogenesis ^[13], and links to mTOR through phosphorylation of TSC2 ^[14] and raptor ^[15]. p38/CSBP was identified as the target of pyridinyl-imidazole anti-inflammatory compounds that block IL-1 and TNF production ^[16], and the Rho-associated kinase p160ROCK inhibitor Y-27632 corrects hypertension in rat models ^[17]. In neurodegeneration, mutations in PINK1 cause early-onset Parkinson's disease, linking mitochondrial function to neuronal survival ^[18], and LRRK2 mutations cause autosomal-dominant parkinsonism with pleomorphic pathology ^[19].

5. Recent advances

Modern work (2017+) has expanded the family's roles in cell death and inflammation. PKCβII was identified by CRISPR and kinase-inhibitor screens as a sensor of lipid peroxidation that phosphorylates and activates ACSL4 to amplify ferroptosis, defining a druggable PKCβII-ACSL4 axis ^[20]. Protein kinase D at the Golgi was shown to phosphorylate NLRP3 and release it from mitochondria-associated membranes to permit inflammasome assembly ^[21]. In necroptosis, solid-state NMR resolved the RIPK1-RIPK3 necrosome as a hetero-amyloid core ^[22]. Mechanistic studies of Parkinson's kinases showed that Rab29 recruits LRRK2 to the trans-Golgi and stimulates its kinase activity, with pathogenic mutants more readily activated ^[23]. CDK9/P-TEFb was found to drive RNA polymerase II CTD hyperphosphorylation through a histidine-rich domain that promotes phase separation ^[24], and mitotic kinases including Aurora B were shown to hyperphosphorylate and silence the DNA sensor cGAS during mitosis ^[25]. The off-target work identifying OTS964 as a CDK11 inhibitor highlights the difficulty of validating kinase drug mechanisms ^[26]. Plant receptor kinases also feature prominently: the H2O2 sensor HPCA1 is an LRR receptor kinase activated by extracellular cysteine modification ^[27], LRR receptor kinases GSO1/GSO2 perceive CIF peptides for Casparian strip formation ^[28], and MAPK cascades integrate plant hormone signaling ^[29].

6. Landmark literature

• The protein kinase complement of the human genome ^[1] — defined the 518-gene human kinome and its disease associations.
• Mechanism of activation of protein kinase B ^[2] and the identification of PDK1 ^[3] — established the Thr308/Ser473 dual-phosphorylation paradigm.
• Inhibition of GSK-3 by insulin mediated by PKB ^[30] — connected Akt to metabolic substrate control.
• AMP-activated protein kinase in metformin action ^[13] — linked a major drug to a metabolic kinase.
• AMPK and mTOR regulate autophagy through Ulk1 ^[31] — defined nutrient-sensing control of autophagy via opposing phosphorylation.

7. Open questions & gaps

The substrate is rich in serine/threonine signaling but thin on the tyrosine kinase subfamily; receptor tyrosine kinases and their oncogenic roles are underrepresented here and should not be extrapolated from this corpus. Mechanistic detail on how individual activation-loop phosphorylations are decoded into substrate specificity remains incompletely captured. The PKC family is acknowledged as molecularly heterogeneous with isoform-specific localization and function ^[32], yet the substrate provides limited isoform-resolved mechanism beyond the PKCβII ferroptosis axis. Therapeutic selectivity is a recurring concern: off-target activity can dominate a drug's mechanism ^[26], and whether selective CDK or kinase inhibition can achieve a therapeutic window remains an open question ^[12]. Finally, the corpus spans metazoan, plant, and fungal kinases without a unifying cross-kingdom mechanistic synthesis, a gap that future structural and chemical-biology work is well positioned to address.